PREVALENCE OF FATIGUE AND IMPACT ON QUALITY OF LIFE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: the VITAL study
Abstract Background Fatigue is one of the most prevalent symptoms among cancer patients. Specifically, in metastatic castration-resistant prostate cancer (mCRPC) patients, fatigue is the most common adverse event associated with current treatments. The purpose of this study is to describe the preval...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2019-10-01
|
Series: | BMC Urology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12894-019-0527-8 |
id |
doaj-41e7b5e50a6347a385ef7e3832765fcd |
---|---|
record_format |
Article |
spelling |
doaj-41e7b5e50a6347a385ef7e3832765fcd2020-11-25T03:54:04ZengBMCBMC Urology1471-24902019-10-011911810.1186/s12894-019-0527-8PREVALENCE OF FATIGUE AND IMPACT ON QUALITY OF LIFE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: the VITAL studyA. Rodríguez Antolín0L. Martínez-Piñeiro1M. E. Jiménez Romero2J. B. García Ramos3D. López Bellido4J. Muñoz del Toro5A. García García-Porrero6F. Gómez Veiga7Urology Department, Hospital Universitario 12 de OctubreUrology Department, Hospital Universitario La PazUrology Department, Hospital Universitario de Puerto RealUrology Department, Complejo Hospitalario Universitario de HuelvaUrology Department, Complejo Hospitalario Universitario de OrenseJanssen Medical Department, Paseo de las 12 estrellas 5-7Janssen Medical Department, Paseo de las 12 estrellas 5-7Urology Department, Hospital Clínico Universitario de Salamanca e Instituto de investigación Biomédica de Salamanca (GITUR-IBSAL)Abstract Background Fatigue is one of the most prevalent symptoms among cancer patients. Specifically, in metastatic castration-resistant prostate cancer (mCRPC) patients, fatigue is the most common adverse event associated with current treatments. The purpose of this study is to describe the prevalence of fatigue and its impact on quality of life (QoL) in patients with CRPC in routine clinical practice. Methods This was a cross-sectional, multicentre study. Male chemo-naïve adults with high-risk non-metastatic (M0) CRPC and metastatic (M1) CRPC (mCRPC) were eligible. Fatigue was measured using the Brief Fatigue Inventory (BFI) and QoL was assessed using the Functional Assessment of Cancer Therapy questionnaire for patients with prostate cancer (FACT-P) and the FACT-General (FACT-G) questionnaire. Data were analysed using Mann-Whitney or Kruskal-Wallis tests (non-parametric distribution), a T-test or an ANOVA (parametric distribution) and the Fisher or chi-squared tests (categorical variables). Results A total of 235 eligible patients were included in the study (74 [31.5%] with M0; and 161 [68.5%] with M1). Fatigue was present in 74%, with 38.5% of patients reporting moderate-to-severe fatigue. Mean FACT-G and FACT-P overall scores were 77.6 ± 16.3 and 108.7 ± 21.4, respectively, with no differences between the CRPC M0 and CRPC M1 subgroups. Fatigue intensity was associated with decreased FACT-G/P scores, with no differences between groups. Among 151 mCRPC patients with available treatment data, those treated with abiraterone-prednisone ≥3 months showed a significant reduction in fatigue intensity (p = 0.043) and interference (p = 0.04) compared to those on traditional hormone therapy (HT). Patients on abiraterone-prednisone ≥3 months showed significantly better FACT-G/P scores than patients on HT (p = 0.046 and 0.018, respectively). Conclusion Our data show a high prevalence and intensity of fatigue and its impact on QoL in chemo-naïve CRPC patients. There is an association between greater fatigue and less QoL, irrespective of the presence or absence of metastasis. Chemo-naïve mCRPC patients receiving more than 3 months of abiraterone acetate plus prednisone showed an improvement of fatigue and QoL when compared to those on traditional HT. Trial registration Not applicable since it is not an interventional study.http://link.springer.com/article/10.1186/s12894-019-0527-8FatigueCastration-resistant prostate cancerQuality of lifeBFI questionnaireFACT-P questionnaire |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
A. Rodríguez Antolín L. Martínez-Piñeiro M. E. Jiménez Romero J. B. García Ramos D. López Bellido J. Muñoz del Toro A. García García-Porrero F. Gómez Veiga |
spellingShingle |
A. Rodríguez Antolín L. Martínez-Piñeiro M. E. Jiménez Romero J. B. García Ramos D. López Bellido J. Muñoz del Toro A. García García-Porrero F. Gómez Veiga PREVALENCE OF FATIGUE AND IMPACT ON QUALITY OF LIFE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: the VITAL study BMC Urology Fatigue Castration-resistant prostate cancer Quality of life BFI questionnaire FACT-P questionnaire |
author_facet |
A. Rodríguez Antolín L. Martínez-Piñeiro M. E. Jiménez Romero J. B. García Ramos D. López Bellido J. Muñoz del Toro A. García García-Porrero F. Gómez Veiga |
author_sort |
A. Rodríguez Antolín |
title |
PREVALENCE OF FATIGUE AND IMPACT ON QUALITY OF LIFE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: the VITAL study |
title_short |
PREVALENCE OF FATIGUE AND IMPACT ON QUALITY OF LIFE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: the VITAL study |
title_full |
PREVALENCE OF FATIGUE AND IMPACT ON QUALITY OF LIFE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: the VITAL study |
title_fullStr |
PREVALENCE OF FATIGUE AND IMPACT ON QUALITY OF LIFE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: the VITAL study |
title_full_unstemmed |
PREVALENCE OF FATIGUE AND IMPACT ON QUALITY OF LIFE IN CASTRATION-RESISTANT PROSTATE CANCER PATIENTS: the VITAL study |
title_sort |
prevalence of fatigue and impact on quality of life in castration-resistant prostate cancer patients: the vital study |
publisher |
BMC |
series |
BMC Urology |
issn |
1471-2490 |
publishDate |
2019-10-01 |
description |
Abstract Background Fatigue is one of the most prevalent symptoms among cancer patients. Specifically, in metastatic castration-resistant prostate cancer (mCRPC) patients, fatigue is the most common adverse event associated with current treatments. The purpose of this study is to describe the prevalence of fatigue and its impact on quality of life (QoL) in patients with CRPC in routine clinical practice. Methods This was a cross-sectional, multicentre study. Male chemo-naïve adults with high-risk non-metastatic (M0) CRPC and metastatic (M1) CRPC (mCRPC) were eligible. Fatigue was measured using the Brief Fatigue Inventory (BFI) and QoL was assessed using the Functional Assessment of Cancer Therapy questionnaire for patients with prostate cancer (FACT-P) and the FACT-General (FACT-G) questionnaire. Data were analysed using Mann-Whitney or Kruskal-Wallis tests (non-parametric distribution), a T-test or an ANOVA (parametric distribution) and the Fisher or chi-squared tests (categorical variables). Results A total of 235 eligible patients were included in the study (74 [31.5%] with M0; and 161 [68.5%] with M1). Fatigue was present in 74%, with 38.5% of patients reporting moderate-to-severe fatigue. Mean FACT-G and FACT-P overall scores were 77.6 ± 16.3 and 108.7 ± 21.4, respectively, with no differences between the CRPC M0 and CRPC M1 subgroups. Fatigue intensity was associated with decreased FACT-G/P scores, with no differences between groups. Among 151 mCRPC patients with available treatment data, those treated with abiraterone-prednisone ≥3 months showed a significant reduction in fatigue intensity (p = 0.043) and interference (p = 0.04) compared to those on traditional hormone therapy (HT). Patients on abiraterone-prednisone ≥3 months showed significantly better FACT-G/P scores than patients on HT (p = 0.046 and 0.018, respectively). Conclusion Our data show a high prevalence and intensity of fatigue and its impact on QoL in chemo-naïve CRPC patients. There is an association between greater fatigue and less QoL, irrespective of the presence or absence of metastasis. Chemo-naïve mCRPC patients receiving more than 3 months of abiraterone acetate plus prednisone showed an improvement of fatigue and QoL when compared to those on traditional HT. Trial registration Not applicable since it is not an interventional study. |
topic |
Fatigue Castration-resistant prostate cancer Quality of life BFI questionnaire FACT-P questionnaire |
url |
http://link.springer.com/article/10.1186/s12894-019-0527-8 |
work_keys_str_mv |
AT arodriguezantolin prevalenceoffatigueandimpactonqualityoflifeincastrationresistantprostatecancerpatientsthevitalstudy AT lmartinezpineiro prevalenceoffatigueandimpactonqualityoflifeincastrationresistantprostatecancerpatientsthevitalstudy AT mejimenezromero prevalenceoffatigueandimpactonqualityoflifeincastrationresistantprostatecancerpatientsthevitalstudy AT jbgarciaramos prevalenceoffatigueandimpactonqualityoflifeincastrationresistantprostatecancerpatientsthevitalstudy AT dlopezbellido prevalenceoffatigueandimpactonqualityoflifeincastrationresistantprostatecancerpatientsthevitalstudy AT jmunozdeltoro prevalenceoffatigueandimpactonqualityoflifeincastrationresistantprostatecancerpatientsthevitalstudy AT agarciagarciaporrero prevalenceoffatigueandimpactonqualityoflifeincastrationresistantprostatecancerpatientsthevitalstudy AT fgomezveiga prevalenceoffatigueandimpactonqualityoflifeincastrationresistantprostatecancerpatientsthevitalstudy |
_version_ |
1724475029492596736 |